Top 1% — Elite
Shaji Kumar
Hematology - Multiple myeloma trials
India
134 H-Index
1,551 Total Impact
Overview
Shaji Kumar is a hematology - multiple myeloma trials specialist with an H-index of 134 at Mayo Clinic (India-origin) (Faculty). Has been published in The Lancet Oncology, Nature Reviews Disease Primers, New England Journal of Medicine. Based in India.
Biography
Shaji Kumar is a leading specialist in Hematology - Multiple myeloma trials at Mayo Clinic (India-origin).
Affiliations & Institutions
Research Impact
5 Publications
0 Total Citations
Publication Timeline
Published In
LeukemiaJ Clin OncolBloodJ Natl Compr Canc NetwLancet Oncol
Key Publications
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Areas of Expertise
Medical Specialties
Media Archive